Evaluating the Significance of Pancreatobiliary Fluorescence In Situ Hybridization Polysomy on Prognosis in De Novo Cholangiocarcinoma.

Autor:	Ji H; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Barr Fritcher EG; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Yin J; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA., Bainter TM; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA., Zemla TJ; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA., Gores GJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Halling KC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Kipp BR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Roberts LR; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Jazyk:	angličtina
Zdroj:	Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2022 Oct 01; Vol. 13 (10), pp. e00523. Date of Electronic Publication: 2022 Oct 01.
DOI:	10.14309/ctg.0000000000000523
Abstrakt:	Introduction: We recently developed a fluorescence in situ hybridization probe set for evaluating suspicious biliary and pancreatic duct strictures (PB-FISH). We aimed to determine whether PB-FISH results in biliary brush cytology specimens are associated with outcomes of patients with cholangiocarcinoma (CCA). Methods: We performed a retrospective study of patients with CCA tested by PB-FISH from January 2015 to August 2018. CCA was stratified by primary sclerosing cholangitis (PSC) into those with (PSC CCA) or without PSC ( de novo CCA). PB-FISH results were categorized as polysomy (gain of multiple loci), nonpolysomy (single locus gain, single locus gain with 9p21 loss, homozygous 9p21 loss, tetrasomy), and disomy (no abnormalities). Overall survival (OS) was estimated using Kaplan-Meier methods and compared between the PB-FISH results using log-rank tests. Cox models were adjusted for age, sex, CA 19-9, cytology results, source of brushing sample, and treatments. Results: Characteristics of 264 eligible patients (median age 60.4; range 18-92) were comparable for patients with PB-FISH polysomy vs nonpolysomy vs disomy. The median OS was similar between disomy, nonpolysomy, and polysomy in the overall population (22.7 vs 22.7 vs 20.3 months, respectively). For de novo CCA, both polysomy and nonpolysomy were associated with worse OS compared with disomy (polysomy: hazard ratio [HR] = 2.09, 95% confidence interval [CI] = 1.14-3.83; nonpolysomy: HR = 2.4, 95% CI = 0.54-2.46; P = 0.027). For PSC CCA, neither polysomy nor nonpolysomy were significantly associated with worse OS (polysomy: 0.90, 95% CI = 0.47-1.75; nonpolysomy: HR = 1.78, CI = 0.71-4.49; P = 0.27). Discussion: PB-FISH alterations are associated with worse survival in de novo CCA, though statistical significance was lost when adjusting for confounding variables. (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu